Ticker Symbol: TOS/TSX
Shares Outstanding: 58,027,389
QUEBEC CITY, June 30, 2011 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in sterilization technology for medical
devices in healthcare settings, announced today that it has
resubmitted documentation to the United States (U.S.) regulatory
authorities for the company's STERIZONE® 125L+ Sterilizer (3M™ Optreoz™ 125-Z). Such a filing is in support of
obtaining clearance for the new generation sterilizer to be sold within
the United States.
"Filing for clearance through the new regulatory process is a
significant step towards the commercialization of our new generation
sterilizer in the U.S.", commented R.M. (Ric) Rumble, CEO of TSO3. "This filing comes after meetings have taken place with the regulators
and additional information has been supplied and reviewed in person.
These meetings have also allowed us to discuss the contents of the
submission and an approach for its filing", added Mr. Rumble. "We are
pleased and confident with the package that has been assembled and we
believe in a successful outcome".
The STERIZONE® 125L+ Sterilizer is covered by a global commercial agreement between
TSO3 and 3M™ under the brand name 3M™ Optreoz™ 125Z. 3M™ has initiated a
phased introduction targeting 15 countries this year, in markets where
regulatory clearances have already been received. Current regulatory
clearances cover Canada, the European Union and selected countries of
Latin America and Asia Pacific.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument
sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital
environment and offers an advantageous replacement solution to other
low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts (including, without
limitation, those regarding the timing or outcome of any financing
undertaken by TSO3) are forward-looking statements that involve certain risks,
uncertainties and hypotheses, including, but not limited to, general
business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other risks and
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
SOURCE TSO3 INC.
For further information:
Source: TSO3 Inc.
Director, Corporate Communications and Investor Relations
(418) 651-0003, Ext. 237